Zydus Cadila receives tentative approval from the USFDA for Carbidopa and Levodopa Extended-Release Capsules


Zydus Cadila has received tentative approval from the USFDA to market Carbidopa and Levodopa Extended-Release Capsules (US RLD – Rytary®) in the strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg.

This medication is used to treat the symptoms of Parkinsons disease (such as shakiness, stiffness, difficulty moving) or Parkinson-like conditions. The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.

The group now has 295 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.388.45 as compared to the previous close of Rs. 365.5. The total number of shares traded during the day was 580094 in over 12249 trades.

The stock hit an intraday high of Rs. 396.3 and intraday low of 367. The net turnover during the day was Rs. 222536097.



Related posts

Leave a Comment